August 20, 2024
Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.
August 20, 2024
Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.
August 19, 2024
More than 6 in 10 adults treated with the investigational CRF1 antagonist crinecerfont reached a physiologic glucocorticoid dose with androstenedione control maintained.
August 19, 2024
Dr Richard Auchus says the ideal treatment for congenital adrenal hyperplasia is a long way off but describes a "block and replace" strategy that holds great promise.
August 19, 2024
Investigators found as much as a 2-fold difference in being diagnosed with dementia across the US, even after controlling for common individual risk factors.
August 16, 2024
Crinecerfont, a CRF1 antagonist, could help reduce glucocorticoid doses for individuals with CAH and improve physical and emotional quality of life, says leading researcher.
August 16, 2024
The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.
August 16, 2024
Patients were the driving force behind the development of the needle-free epinephrine nasal spray, Casale says; he answers more questions with primary care in mind.
August 15, 2024
If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.
August 15, 2024
The approval of neffy (epinephrine nasal spray) could help individuals and caregivers act sooner and feel safer treating a type 1 allergic reaction.